Carregant...
524. Understanding the Treatment of Carbapenem-Resistant Enterobacteriaceae (CRE) Infections in the United States (US): Insights from a Survey of Hospital-Based Pharmacists
BACKGROUND: New anti-CRE antibiotics (ceftazidime–avibactam, C-A; meropenem-vaborbactam, M-V; plazomicin, PLZ) are associated with improved outcomes and lower toxicity than polymixins (PMs; colistin; polymyxin B) in treating CRE infections. We previously demonstrated that ~40% (range: 28–71%) and ~2...
Guardat en:
| Publicat a: | Open Forum Infect Dis |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6811047/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.593 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|